SCHEMBL3486133

SCHEMBL3486133

Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)nc2ccc(Cl)nn12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 9/20 0.50
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TP53 P04637 2/20 0.44
RECQL P46063 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
ATM Q13315 1/20 0.44
CSNK1D P48730 1/20 0.44
CSNK1E P49674 1/20 0.44
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486135 0.78 MAP3K5 (0.54) MAP3K5NPC1RAB9ACYP1A2CYP2D6
SCHEMBL3485883 0.76 MAP3K5 (0.65) MAP3K5NPC1RAB9ASMN1; SMN2TP53
SCHEMBL1524769 0.75 MAP3K5 (0.45) MAP3K5NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL18536813 0.71 KDM4E (0.43) SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1523962 0.69 MAP3K5 (0.54) MAP3K5NPC1RAB9ASMN1; SMN2TP53
SCHEMBL17509926 0.69 NPC1 (0.55) MAP3K5NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL1524348 0.68 MAP3K5 (0.55) MAP3K5NPC1RAB9ASMN1; SMN2TP53
SCHEMBL6619842 0.67 HSD17B10 (0.40) NPC1RAB9ASMN1; SMN2CYP2C9CYP2C19
SCHEMBL14051568 0.67 KCNQ3 (0.74) NPC1RAB9ASMN1; SMN2
SCHEMBL3486097 0.67 MAP3K5 (1.00) MAP3K5NPC1RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 MAP3K5 42/4885NPC1 2569/4885RAB9A 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.